Barclays Raises Merck (MRK) Price Target to $180
Key Points
- Barclays increased its price target on Merck from $150 to $180, keeping an Overweight rating.
- Barclays's $180 price target implies 23.91% upside from Merck & Co., Inc.'s ($MRK) current $145.27 share price.
- Merck recently traded at $145.27, which is about 2.5% above its closing price of $141.76 on the same day.
- Analysts currently have a consensus price target of $159.76 for Merck, with 25 opinions suggesting a buy recommendation.
Get Merck & Co. text alerts
We text you when insiders, Congress, analysts or big funds move on $MRK.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Merck & Co., Inc. alert may contain errors. Disclosures
On October 26, 2026, Barclays raised its price target on Merck & Co., Inc. (MRK) to $180 from $150, while maintaining an Overweight rating. This update comes as the firm continues to express confidence in Merck's business outlook. The information is based on Barclays' research note from the same day.
MRK
Merck & Co., Inc.
Barclays vs. the S&P 500
Hypothetical returns from Barclays's disclosed trades, not real profit or advice. How we model this.
Barclays' Call on Merck
Barclays raised its price target on Merck from $150 to $180. This change signals the firm's positive outlook on Merck's performance in the healthcare sector, particularly given its strong pharmaceutical offerings. The updated target reflects Barclays' belief in the company's growth potential amid recent earnings results.
Other Institutional Activity in Merck
Several other funds have also adjusted their positions in Merck recently. Wilmington Savings Fund Society, FSB reduced its holdings by 19,001 shares, ending with 204,655 shares valued at about $29.7 million. Mondrian Investment Partners cut its stake by 889,899 shares, now holding 584,046 shares worth approximately $84.9 million. Evergreen Capital Management decreased its position by 69,731 shares, bringing its total to 188,787 shares valued at about $27.6 million.
Merck & Co., Inc. Stock Down 1.3%
Merck's recent trading price is $145.27, which is about 2.5% above its closing price of $141.76 on October 26, 2026. The stock is currently below its 50-day moving average of $146.64, but it is above its 200-day moving average of $125.86. Merck's shares are also about 7.4% below their 52-week high of $156.92, yet 77.1% above the 52-week low of $82.01.
$MRK price target
Merck & Co., Inc. daily closes and this analyst's $180 target. Not advice.
Recent Earnings
Merck reported trailing twelve-month revenue of about $66.6 billion, with an earnings per share (EPS) of $1.24. The company has shown a revenue growth of 5.1% year-over-year and a net margin of 4.8%. Merck's next earnings report is scheduled for October 29, 2026.
Insider Buying and Selling at Merck & Co., Inc.
Chirfi Guindo, an officer at Merck, sold 15,000 shares at $131.00 each on August 6, 2026, totaling about $1.97 million. General Counsel Jennifer L Zachary sold 80,315 shares at an average price of $133.46 on August 12, 2026, valued at approximately $10.7 million. Richard Robert Deluca Jr., another officer, sold 45,320 shares on August 12, 2026, valued at about $5.9 million. On August 13, 2026, Chirfi Guindo sold an additional 10,000 shares at $135.00 each, totaling around $1.35 million.
Analysts Set New Price Targets
On October 26, 2026, Barclays maintained its Overweight rating for Merck and raised the price target to $180. Earlier in the month, Morgan Stanley maintained its Overweight rating with a target of $177, while Cantor Fitzgerald, Citigroup, and RBC Capital maintained Neutral ratings with targets of $145. The consensus price target among analysts is currently $159.76, reflecting a strong buy recommendation based on 25 opinions.
About Merck
Merck & Co., Inc. is a global healthcare company based in Rahway, NJ. It focuses on developing and providing various pharmaceutical products, including vaccines and medicines for different health conditions. The recent adjustments in price targets show analysts' confidence in Merck's future performance in the competitive healthcare sector.
Bottom Line
Investors should keep an eye on Merck's upcoming earnings report on October 29, 2026, as well as any further analyst ratings or institutional activity. The adjustments in price targets indicate a positive outlook for the company, aligning with its solid performance in the healthcare market.
Related Filing Alerts
Source: Barclays's rating change on $MRK (Oct 26, 2026). Written by software, not financial advice. How we make alerts